POLRMT and cancer: While mitochondrial transcription may be impaired by different mechanisms, exploring the similarities and differences between ClpP agonists and POLRMT inhibitors may ultimately help understand the mechanism of action of both drug classes and evaluate the feasibility of targeting this mitochondrial process in cancer cells.